Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of padoprazan (ID120040002) in healthy volunteers
NCT05663879Phase 1Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DW4421-1 in gastroesophageal reflux disease (GERD) (10 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Number of participants with Serious Adverse Events (SAEs), Number of participants with Adverse Events (AEs) and 2 more. Status: unknown.
02
Drugs
DW4421-1
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05663879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663879.